{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"groups":[{"description":"Cyclophosphamide/carboplatin/etoposide; vincristine/doxorubicin/cyclophosphomide; x 30 weeks; XRT.","id":"OG000","title":"UH-1"},{"description":"Window therapy of vincristine/irinotecan;Cyclophosphamide/carboplatin/etoposide; vincristine/doxorubicin/cyclophosphomide; x 30 weeks; XRT.","id":"OG001","title":"Window/UH-1"}],"paramType":"NUMBER","populationDescription":"Eligible patients with reported INI1 mutation data.","reportingStatus":"POSTED","timeFrame":"At baseline","title":"Number of Patients With INI1 Mutations in Renal and Extrarenal Malignant Rhabdoid Tumor by Fluorescent in Situ Hybridization","type":"SECONDARY","unitOfMeasure":"Count participants"}